Postdoctoral clinical research training fellowship – UK Research and Innovation
November 26, 2025
Conference on healthcare management in Aragon to promote the optimization of health processes
November 27, 2025
Alberto J. Schuhmacher, a researcher in the Molecular Oncology group, receives 50.000 euros to advance a nano ADC against metastatic breast cancer.
The seventh edition of the M. Chiara Giorgetti Award for research in metastatic breast cancer has announced its winning projects. The call for proposals, promoted by the Metastatic Breast Cancer AssociationIt promotes new avenues of knowledge and better future options for people living with the disease. This year, the Evaluation Committee has recognized three proposals of great scientific value, with a total funding of 280.000 euros.
El first prize, endowed with 150.000 Euros, it has been for the Dr. Joaquín Gavilá (Valencian Institute of Oncology Foundation), for a descriptive study of long-responder patients with luminal metastatic breast cancer, aimed at the design of a future clinical trial that evaluates therapeutic de-escalation guided by ctDNA.
El second prize, with 80.000 Euros, has received it Dr. Antoni Celià (Hospital del Mar Research Institute – HMRI) for a project focused on tumor TIM3-mediated chemotherapy resistance as a therapeutic target in the adjuvant context, with the aim of preventing metastasis.
El third prize, with 50.000 Euros, has been awarded to Dr. Alberto J. Schuhmacher, researcher of Molecular Oncology Group of the Aragon Health Research Institute, for the project Amparo, dedicated to the development of a nano ADC for the treatment of metastatic breast cancer.
The project Amparo It takes its name from Amparo Magallón, a member of the Association in Zaragoza, whose experience helped the team understand the importance of specifically investigating metastasis in breast cancer and the need to raise awareness of lesser-known forms of the disease. In this work, the IIS Aragón team develops nanoantibodies that act as “drones” capable of attaching directly to the tumor and transporting ultratoxic chemotherapies, selected based on the genetic alterations characteristic of these tumors.
Within the project, these targeted proteins will be manufactured and their efficacy evaluated in different experimental models. The work will involve state-of-the-art 3D cell cultures which are being developed in collaboration with groups from the Institute, and with murine models with metastases that exhibit tropism for specific organsThis will allow for the study of more precise and targeted administration of these treatments. Furthermore, the project will incorporate the isotope labeling to visualize the path of the new immunotherapy through CT scanner, with the aim of better understanding its distribution in the body.
